A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib Over 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

The aim of the current study is to investigate the efficacy and safety of nintedanib over 52
weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) defined as
patients who present with features of diffuse fibrosing lung disease of >10% extent on
high-resolution computed tomography (HRCT) and whose lung function and respiratory symptoms
or chest imaging have worsened despite treatment with unapproved medications used in clinical
practice to treat ILD. There is currently no efficacious treatment available for PF-ILD.
Based on its efficacy and safety in Idiopathic Pulmonary Fibrosis (IPF), it is anticipated
that Nintedanib will be a new treatment option for patients with PF-ILD.